Many metabolic things in humans appear to indicate that the human population is very heterogeneous wrt which interventions work and which cause harm. Perhaps the most famous set of trials indicating this was The HERITAGE Study.
But it shows up in other, smaller, ways too. Eg T2D doesn’t really look like a single disease. Responses to insulin tests even in similar HbA1c patients vary widely, some ppl lose muscle response, some lose insulin capability, … . It’s been surprising to me that no biotech, of which I’m aware, has tried to target some specific etiology.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.